Bosutinib‐associated interstitial lung disease and pleural effusion: A case report and literature review

Abstract

Abstract Bosutinib is a tyrosine kinase inhibitor approved for the management of chronic myeloid leukemia (CML). Interstitial lung disease and pleural effusion are pulmonary side effects of TKIs rarely associated with bosutinib treatment.

Keywords

• bosutinib
• bosutinib‐related interstitial lung disease
• pleural effusion
• tyrosine kinase inhibitors